Media
Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)
GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug…
Isofol appoints nomination committee ahead of the Annual General Meeting 2022
GOTHENBURG, Sweden, November 19, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that…
Isofol Medical AB (publ) publishes interim report for January – September 2021
GOTHENBURG, Sweden, November 11, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report…
Upcoming Events
- December 16, 2021 - December 16, 2021
DNB Nordic Healthcare Conference 2021
Isofol will attend the event with a presentation of Isofol and a Q & A sessions. Investors will have the opportunity to meet management in one-on-one or small group meetings. - January 20, 2022 - January 20, 2022
Redeye Fight cancer seminar 2022 - February 24, 2022 - February 24, 2022
Interim Report Q4 2021